NCT06181513RecruitingEarly phase 1
Probiotics in Mild Alzheimer's Disease
Effect of Probiotics on Cognitive Functioning of Patients With Mild Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 5 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 8 Dec 2023
- Start date
- 19 Dec 2022
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- University of Nicosia
- Diseases
- Alzheimer disease
- NCT number
- NCT06181513
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 19 Dec 2022 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of systemic antibiotics in the previous 6 months
- corticosteroid use
- immune stimulating medications
- probiotics consumption in the previous 6 months.
- radiation
Other illness
- other neurological disease
- relevant psychiatric disorders (e.g. major depression)
- gastrointestinal/metabolic conditions
- history of alcohol/substance dependence
- structural heart disease
- active intestinal disease
Other
- Inability to give consent
- immunosuppressive agents
- immunosuppression
- neutropenia
Who the study is looking for
- Adults ≥65 years, able to give consent
- Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
- approximately equal male:female ratio
Age in the registry: 65 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Cyprus Institute of Neurology and Genetics Coordinator of this site? Confirm its status | Nicosia | Cyprus | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.